Catalent has started making viral vectors to support trials of PBGM01, a gene therapy for the rare lysosomal storage disease GM1 being developed by Passage Bio.  The US contract development and manufacturing organization (CDMO) set up a dedicated manufacturing suite at for Passage at its facility in Harmans, Maryland in August. Work since then has focused on bringing the suite online and validating it for the production of the AAVhu68 vector. The vector is used to deliver a modified DNA…